Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mahmut Muslumanoglu

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
European Journal of Radiology Open|December 9, 2020
Comparison between body composition parameters and response to neoadjuvant chemotherapy by using pre-treatment PET CT in locally advanced breast cancerInci Kizildag Yirgin, Duygu Has, Gozde Arslan, et al.
Medicina (Kaunas, Lithuania)|September 27, 2025
Curcumin as an Epigenetic Modulator: Suppression of Breast Cancer via the Hsa_circ_0001946/MiR-7-5p/Target Gene AxisAsmaa Abuaisha, Murat Kaya, Ilknur Suer, et al.
Current Medical Imaging|February 25, 2022
Abbreviated and Standard Breast MRI in Neoadjuvant Chemotherapy Response Evaluation: A Comparative StudyInci Kizildag Yirgin, Gulgun Engin, Şeyma Yildiz, et al.
World Journal of Surgical Oncology|October 31, 2024
Axillary lymph node dissection is not required for breast cancer patients with minimal axillary residual disease after neoadjuvant chemotherapyMahmut Muslumanoglu, Baran Mollavelioglu, Neslihan Cabioglu, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 26, 2020
The role of loco-regional treatment in long-term quality of life in de novo stage IV breast cancer patients: protocol MF07-01QAtilla Soran, Aykut Soyder, Serdar Ozbas, et al.
Clinical Breast Cancer|December 2, 2011
Predicting the likelihood of nonsentinel lymph node metastases in triple negative breast cancer patients with a positive sentinel lymph node: Turkish Federation of Breast Disease Associations protocol MF09-01Serdar Ozbas, Vahit Ozmen, Abdullah Igci, et al.
Annals of Surgical Oncology|May 20, 2018
Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01Atilla Soran, Vahit Ozmen, Serdar Ozbas, et al.
Cancer|October 30, 2024
Combined analysis of the MF18-02/MF18-03 NEOSENTITURK studies: ypN-positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is providedMahmut Muslumanoglu, Neslihan Cabioglu, Abdullah Igci, et al.
The Lancet. Oncology|December 25, 2025
Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort studyGiacomo Montagna, Michael Alvarado, Sara Myers, et al.
Annals of Surgical Oncology|December 2, 2024
Breast Cancer Recurrence in Initially Clinically Node-Positive Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in the NEOSENTITURK-Trials MF18-02/18-03Neslihan Cabioglu, Hasan Karanlik, Abdullah Igci, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
European Journal of Radiology Open|December 9, 2020
Comparison between body composition parameters and response to neoadjuvant chemotherapy by using pre-treatment PET CT in locally advanced breast cancerInci Kizildag Yirgin, Duygu Has, Gozde Arslan, et al.
Medicina (Kaunas, Lithuania)|September 27, 2025
Curcumin as an Epigenetic Modulator: Suppression of Breast Cancer via the Hsa_circ_0001946/MiR-7-5p/Target Gene AxisAsmaa Abuaisha, Murat Kaya, Ilknur Suer, et al.
Current Medical Imaging|February 25, 2022
Abbreviated and Standard Breast MRI in Neoadjuvant Chemotherapy Response Evaluation: A Comparative StudyInci Kizildag Yirgin, Gulgun Engin, Şeyma Yildiz, et al.
World Journal of Surgical Oncology|October 31, 2024
Axillary lymph node dissection is not required for breast cancer patients with minimal axillary residual disease after neoadjuvant chemotherapyMahmut Muslumanoglu, Baran Mollavelioglu, Neslihan Cabioglu, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 26, 2020
The role of loco-regional treatment in long-term quality of life in de novo stage IV breast cancer patients: protocol MF07-01QAtilla Soran, Aykut Soyder, Serdar Ozbas, et al.
Clinical Breast Cancer|December 2, 2011
Predicting the likelihood of nonsentinel lymph node metastases in triple negative breast cancer patients with a positive sentinel lymph node: Turkish Federation of Breast Disease Associations protocol MF09-01Serdar Ozbas, Vahit Ozmen, Abdullah Igci, et al.
Annals of Surgical Oncology|May 20, 2018
Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01Atilla Soran, Vahit Ozmen, Serdar Ozbas, et al.
Cancer|October 30, 2024
Combined analysis of the MF18-02/MF18-03 NEOSENTITURK studies: ypN-positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is providedMahmut Muslumanoglu, Neslihan Cabioglu, Abdullah Igci, et al.
The Lancet. Oncology|December 25, 2025
Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort studyGiacomo Montagna, Michael Alvarado, Sara Myers, et al.
Annals of Surgical Oncology|December 2, 2024
Breast Cancer Recurrence in Initially Clinically Node-Positive Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in the NEOSENTITURK-Trials MF18-02/18-03Neslihan Cabioglu, Hasan Karanlik, Abdullah Igci, et al.
Pageof 10